PEGASUS Clinical Study of AMX0035 in Alzheimer’s Disease

2019, 2020, 2021

The Amylyx PEGASUS Alzheimer’s disease phase 2 clinical trial will enroll 100 patients in sites across the country in a double-blind protocol to test a combination therapy. AMX0035 is composed of two known compounds that together address endoplasmic reticulum and mitochondrial stress, both of which have been implicated in neuronal death and degradation. The trial is enrolling patients who already are experiencing mild cognitive impairment or early dementia. Readout is anticipated in 2021.

Funding to Date



Clinical Trials, Drug Development